$ALHC

KONOWIECKI JOSEPH S sold $550K of ALHC

KONOWIECKI JOSEPH S (EVP, Corporate Affairs) sold 25,000 shares of Alignment Healthcare, Inc. (ALHC) at $22.00 ($0.55M total) on 2026-06-18 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · KONOWIECKI JOSEPH S
Published Jun 18, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 11:52 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ALHC
Neutral
medium confidence
Mentioned
$ALHC
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ALHCNeutralLow
01

Why it matters

The newest fact is the specific sale size, price ($22.00), and that it was executed under a pre-arranged 10b5-1 plan on June 18.

02

Market read

Traders may monitor insider activity, but this disclosure alone is unlikely to drive a fundamental repricing without corroborating news.

03

What to watch

The filing does not state any change in business outlook, and the article provides no context on total insider holdings beyond post-transaction shares.

Relevance 4/10Novelty 3/10Timing: filed June 18, after-hours/late session timing for traders reviewing insider flows

Background

This is an SEC Form 4 insider transaction disclosure for Alignment Healthcare, Inc. (ALHC).

Company-level read

Ticker impact

$ALHCNeutralMedium confidence
Context

Alignment Healthcare disclosed an EVP corporate affairs open-market sale of 25,000 shares at $22.00 on a 10b5-1 plan filed June 18.

Expected impact

Limited near-term impact; any reaction is likely muted unless paired with other company-specific news.

Evidence & confidence

Form 4 shows a scheduled sale (10b5-1) with no accompanying guidance, deal, or regulatory development in the text.

Market effects

No sector read-through is provided beyond a single-company insider transaction.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a 10b5-1 plan, it may reflect liquidity planning rather than bearish expectations.

Key entities

  • Alignment Healthcare, Inc.

    Company whose insider sale is disclosed via Form 4.

  • KONOWIECKI JOSEPH S

    EVP, Corporate Affairs; reported open-market sale of 25,000 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ALHCMed

Why Alignment Healthcare (ALHC) Stock Is Up Today

Alignment Healthcare (ALHC) shares rose 8.6% after its subsidiary announced a new Medicare Advantage plan in Los Angeles and Orange counties. Analyst Ryan Langston lowered his price target to $12 but maintained a Buy rating, citing inpatient utilization pressure. The stock had fallen 13.4% the previous day due to a downgrade and regulatory concerns.

$HUMMedAI 8/10

Humana Rebounds in Medicare Advantage Star Ratings for 2027

Humana's Medicare Advantage star ratings improved significantly for 2027, with 93% of members in plans rated 4 stars or higher, up from 41% in 2026. This could generate $3B+ in additional revenue in 2028, according to TD Cowen. Alignment Healthcare saw a major decline, potentially losing $170M in revenue. CMS changed its star ratings methodology for 2027.

$ALHCHigh

ALHC Stock Slides As Legal, Cost, And Rating Pressures Mount

Alignment Healthcare Inc. (ALHC) stock fell 14.75% on October 9, 2026, amid concerns over Medicare Advantage reimbursement pressures, legal issues, and cost challenges. The company reported $1.34B in revenue and $36.6M in net income for the latest quarter, but negative cash flow raised concerns. CMS's 2027 Star Ratings and a whistleblower's accounting allegations further pressured the stock, with Barclays cutting its price target to $10.